2014. A cross-sectional observational study to establish the association between ECOG performance status and age and administration of doublet or triplet chemotherapy containing Xeloda® (capecitabine) in advanced gastric cancer patients. European Journal of Oncology and Environmental Health. 18, 4 (Jun. 2014), 173–180.